Brainstorm Cell Therapeutics Stock Last Dividend Paid
BCLI Stock | USD 1.74 0.12 7.41% |
Brainstorm Cell Therapeutics fundamentals help investors to digest information that contributes to Brainstorm Cell's financial success or failures. It also enables traders to predict the movement of Brainstorm Stock. The fundamental analysis module provides a way to measure Brainstorm Cell's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Brainstorm Cell stock.
Brainstorm | Last Dividend Paid |
Brainstorm Cell Therapeutics Company Last Dividend Paid Analysis
Brainstorm Cell's Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.
More About Last Dividend Paid | All Equity Analysis
Last Dividend | = | Last Profit Distribution AmountTotal Shares |
Brainstorm Last Dividend Paid Driver Correlations
Understanding the fundamental principles of building solid financial models for Brainstorm Cell is extremely important. It helps to project a fair market value of Brainstorm Stock properly, considering its historical fundamentals such as Last Dividend Paid. Since Brainstorm Cell's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Brainstorm Cell's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Brainstorm Cell's interrelated accounts and indicators.
Click cells to compare fundamentals
Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.
Competition |
Based on the recorded statements, Brainstorm Cell Therapeutics has a Last Dividend Paid of 0.0. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Brainstorm Cell Current Valuation Drivers
We derive many important indicators used in calculating different scores of Brainstorm Cell from analyzing Brainstorm Cell's financial statements. These drivers represent accounts that assess Brainstorm Cell's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Brainstorm Cell's important valuation drivers and their relationship over time.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Market Cap | 1.1B | 1.4B | 2.0B | 176.2M | 158.6M | 150.7M | |
Enterprise Value | 1.1B | 1.4B | 2.0B | 175.6M | 158.0M | 150.1M |
Brainstorm Fundamentals
Return On Equity | -11.22 | ||||
Return On Asset | -1.78 | ||||
Current Valuation | 10.6 M | ||||
Shares Outstanding | 5.7 M | ||||
Shares Owned By Insiders | 9.00 % | ||||
Shares Owned By Institutions | 13.89 % | ||||
Number Of Shares Shorted | 173.85 K | ||||
Price To Earning | (16.00) X | ||||
Price To Book | 65.82 X | ||||
EBITDA | (16.93 M) | ||||
Net Income | (17.19 M) | ||||
Cash And Equivalents | 12.24 M | ||||
Cash Per Share | 0.34 X | ||||
Total Debt | 672 K | ||||
Debt To Equity | 0.60 % | ||||
Current Ratio | 1.63 X | ||||
Book Value Per Share | (1.21) X | ||||
Cash Flow From Operations | (20.46 M) | ||||
Short Ratio | 1.25 X | ||||
Earnings Per Share | (3.45) X | ||||
Target Price | 23.45 | ||||
Number Of Employees | 29 | ||||
Beta | 0.39 | ||||
Market Capitalization | 9.92 M | ||||
Total Asset | 4.21 M | ||||
Retained Earnings | (215.01 M) | ||||
Working Capital | (5.69 M) | ||||
Current Asset | 16.79 M | ||||
Current Liabilities | 2.95 M | ||||
Net Asset | 4.21 M |
About Brainstorm Cell Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Brainstorm Cell Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Brainstorm Cell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Brainstorm Cell Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Brainstorm Cell Ther offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Brainstorm Cell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Brainstorm Cell Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Brainstorm Cell Therapeutics Stock:Check out Brainstorm Cell Piotroski F Score and Brainstorm Cell Altman Z Score analysis. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brainstorm Cell. If investors know Brainstorm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brainstorm Cell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.45) | Return On Assets (1.78) | Return On Equity (11.22) |
The market value of Brainstorm Cell Ther is measured differently than its book value, which is the value of Brainstorm that is recorded on the company's balance sheet. Investors also form their own opinion of Brainstorm Cell's value that differs from its market value or its book value, called intrinsic value, which is Brainstorm Cell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brainstorm Cell's market value can be influenced by many factors that don't directly affect Brainstorm Cell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brainstorm Cell's value and its price as these two are different measures arrived at by different means. Investors typically determine if Brainstorm Cell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brainstorm Cell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.